REM Sleep Behavior Disorder
60
17
22
16
Key Insights
Highlights
Success Rate
89% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
3.3%
2 terminated out of 60 trials
88.9%
+2.4% vs benchmark
8%
5 trials in Phase 3/4
19%
3 of 16 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 16 completed trials
Clinical Trials (60)
Neuroplasticity in RBD
A Multimodal Prospective Cohort Study of Parkinsonism
An Exploratory Study of the Potential for Rational Immune System Manipulation to Prevent Emergence of Synucleinopathy Manifestations in Persons With REM Sleep Behavior Disorder (RBD)
Implementing a National Biobank of PD With WGS and Functional Assessment of Polygenic Inheritance by iPSC Technology
Unmet Needs Among Patients With Isolated REM Sleep Behavior Disorder (iRBD) and Their Significant Others
Parkinson's Disease Biomarker Study
Behavioral Treatment for Nightmares in REM Sleep Behavior Disorder
DaTSCAN Imaging in Aging and Neurodegenerative Disease
Terazosin and Parkinson's Disease Extension Study
Cardiac Changes in Early Parkinson's Disease: A Follow up Study
Adrenergic Blockers for Cardiac Changes in Early Parkinson's Disease (Protocol 53136)
Terazosin Effect on Cardiac Changes in Early Parkinson's Disease
IMPACT 360 for Parkinson's Disease
MIBG in Aging and Neurologic Disorders
Identification of Prodromal Neurodegeneration in Serotonergic-Induced REM Sleep Behavior Disorder
Natural History Study of Synucleinopathies
Slow-SPEED-NL: Slowing Parkinson's Early Through Exercise Dosage-Netherlands
Evaluating the Efficacy and Safety of PROSOMNIA Sleep Therapy™ in Patients With Sleep Deprivation and Chronic Insomnia
Intestinal Immunity in Neurologic Disease
Effect of PXS-4728A on Microglia Activation in Participants With Isolated Rapid Eye Movement Sleep Behaviour Disorder